Date:10/28/2009

----- -- ----- ----- Total operating expenses 70,295 70,674 189,517 227,529 ------ ------ ------- ------- Income (loss) from operations 2,351 10,133 7,700 10,045 Equity in the loss of BioMarin/Genzyme LLC (572) (680) (1,692) (1,773) Interest income 3,407 1,012 13,157 4,051 Interest expense (4,105) (2,880) (12,297) (11,375) Impairment loss on equity investments - - - (5,848) Net gain from sale of investments - - - 1,585 --- --- --- ----- Income (loss) before income taxes 1,081 7,585 6,868 (3,315) Provision for income taxes 252 945 543 1,884 --- --- --- ----- Net income (loss) $829 $6,640 $6,325 $(5,199) ==== ====== ====== ======= Net income (loss) per share, basic $0.01 $0.07 $0.06 $(0.05) ===== ===== ===== ====== Net income (loss) per share, diluted $0.01 $0.06 $0.06 $(0.05) ===== ===== ===== ====== Weighted average common shares outstanding, basic 99,537 100,331 98,705 100,098 ====== ======= ====== ======= Weighted average common shares outstanding, diluted 103,403 101,906 103,916 100,189 ======= ==
'/>"/>

SOURCE BioMarin Pharmaceutical Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine technology :

1. BioMarin to Present at the Oppenheimer Healthcare Conference
2. BioMarin Acquires Huxley Pharmaceuticals, Inc.
3. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
4. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
5. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
7. BioMarin Announces FDA Approval for Kuvan
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Rigel Announces Presentations at Two Investor Conferences
10. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
11. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call